在再灌注之前或同时应用细胞保护剂,是防治或减轻心肌缺血再灌注损伤的主要措施。Mg2+是体内300多种酶的辅酶,具有多种生理功能。近年研究表明,镁制剂作为细胞保护剂应用于再灌注损伤,可发挥良好的心肌保护作用。现就镁在心肌缺血再灌注IR损伤中的保护作用及其作用机制以及在AMI方面的临床应用情况综述如下。 Applying cytoprotective agents before or simultaneously with reperfusion is the primary measure to prevent or reduce myocardial ischemia-reperfusion injury. Mg2 + is more than 300 kinds of enzyme coenzyme in the body, with a variety of physiological functions. In recent years, studies have shown that magnesium as a cell protectant applied to reperfusion injury, can play a good role in myocardial protection. Now on magnesium in myocardial ischemia-reperfusion injury in IR and its mechanism of action and in the clinical application of AMI are summarized below.